Difference between revisions of "Lung Cancer Trials"

From DolceraWiki
Jump to: navigation, search
 
(No difference)

Latest revision as of 21:09, 6 October 2011

To go back to the main page, click here

S.No Drug Name Biological Name Developer Current Development Phase Additional Information Start Date Completion Date Source
11 - Antibody Millennium
Pharmaceuticals 		I - - - -
12 - CEA DNA Cancer
Vaccine 		Merck/Vical I - - - -
13 - DCVax-Lung Northwest
Biotherapeutics 		I - - - -
14 - MEDI-543/EphA2
Vaccine 		MedImmune I - - - -
15 - AdhTAP TapImmune Preclinical - - - -
16 - ADV-005 Advantagene Preclinical - - - -
17 - CEA Dendreon Preclinical - - - -
18 - PSMA/PRAME MannKind Corporation I Completed
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers. 		2007 2009 Source
19 - AVX703 AlphaVax I/II The primary objective of this protocol is to determine the safety of immunization with CEA(6D) VRP in patients with advanced or metastatic CEA expressing malignancies. 2007 2010 Source
20 - HSPPC-96 Antigenics II The goal of this trial is to determine the safety of HSPPC-96 and which route of administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic agent made from an individual patient’s tumor. 2003 2007 Source
21 - BMS-936558 (MDX-1106) Bristol-Myers Squibb I The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. 2008 2015 Source
22 - NY-ESO-1 plasmid DNA Cancer Vaccine Ludwig Institute for Cancer Research I Completed: To estimate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by PMED in patients with tumor type known to express NY-ESO-1 or LAGE-1 using frequency, severity, and duration of treatment-related adverse effects as endpoints. 2004 2007 Source
23 - HyperAcute-Lung Cancer Vaccine NewLink Genetics II Terminated. To determine the response rate of the administration of HyperAcute-Lung Cancer Vaccine for subjects with stage IIIB or stage IV non-small cell lung cancer who have been treated with first line platinum-doublet therapy and have responded or are considered to have stable disease. 2007 2011 Source
24 Cyclophosphamide CG8123 Cell Genesys II Completed: The main purpose of this research study is to determine if a vaccine made from a patient’s lung cancer tumor cells will be effective in making the cancer shrink or disappear. 2003 2006 Source
25 - Stimuvax, Placebo EMD Serono, Merck KGaA III Active: The purpose of this study is to determine whether the cancer vaccine Stimuvax in addition to best supportive care is effective in prolonging the lives of patients with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. 2006 2014 Source
26 - CV9201 CureVac GmbH I/II The phase I part of the study consists of a dose escalation phase, in which the recommended dose (RD) for the phase IIa part of the study will be established based on the incidence of dose-limiting toxicities (DLT). In the phase IIa part of the study, additional patients will be included at the RD, to confirm the safety and explore the activity of that dose. This study will take place in Switzerland (2 sites) and Germany (11 sites). 2009 2012 Source
27 - HLA-A*2402 restricted epitope peptides CDCA1 and KIF20A emulsified with Montanide ISA 51 Shiga University I The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A*2402 restricted epitope peptides CDCA1 and KIF20A emulsified with Montanide ISA 51 for advanced small cell lung cancers. 2010 2013 Source
28 - L-BLP25 or BLP25 liposome vaccine (Stimuvax), Placebo Merck KGaA III Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine)* clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, START and INSPIRE. 2009 2018 Source
29 - HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides Shiga University I The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A*0201 or HLA-A*0206 restricted epitope peptides URLC10 emulsified with Montanide ISA 51 for advanced non-small cell lung cancers. 2010 2013 Source
30 - HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides Shiga University I The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A*2402 restricted epitope peptides URLC10, CDCA1, and KIF20A emulsified with Montanide ISA 51 for advanced non-small cell lung cancers. 2010 2013 Source
31 - GVAX lung cancer vaccine Southwest Oncology Group, National Cancer Institute (NCI) II This phase II trial is studying vaccine therapy to see how well it works in treating patients with stage IIIB or stage IV bronchoalveolar (lung) cancer. 2004 Ongoing Source
32 1650-G Vaccine - University of Kentucky II The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of initial definitive therapies. 2006 2009 Source
33 - Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated Hadassah Medical Organization I/II This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with colorectal, gastric, ovarian, breast or lung epithelial cancer - - Source
34 - Immunotherapeutic GSK2302032A, different formulations GlaxoSmithKline I The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery. 2010 2014 Source
35 - Interleukin-2 National Cancer Institute (NCI) II Phase II trial to study the effectiveness of a vaccine made with the patients’ white blood cells mixed with tumor proteins in treating patients who have advanced cancer. - - -
36 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
37 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
38 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
39 Detox-B adjuvant, ras peptide cancer vaccine - National Cancer Institute (NCI) I Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer. 1995 Ongoing Source
40 - Ras peptide cancer vaccine, sargramostim Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI) I Phase I trial to study the effectiveness of vaccine therapy and sargramostim in treating patients who have non-small cell lung cancer. 1999 Ongoing Source
41 - carcinoembryonic antigen RNA-pulsed DC cancer vaccine Duke University, National Cancer Institute (NCI) I Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic cancer that has not responded to previous treatment. 2000 2009 Source
42 - GM.CD40L.CCL21 Vaccinations, GM.CD40L cells Vaccinations H. Lee Moffitt Cancer Center and Research Institute II The purpose of this study is to find out what effects (good and bad) a tumor vaccine used in combination with GM.CD40L and CCL21 have on the patient and their cancer. We also want to find out if the vaccine and the drugs can boost the immune system of these patients and how their immune system reacts, both before and after the vaccine treatment. 2011 2015 Source
43 ETBX-011 AD5 CEA Vaccine Etubics Corporation I/II The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 [E1-, E2b-]-CEA(6D)or ETBX-011 and is made by Etubics. This vaccine is based on a virus called an adenovirus but it has been changed to express the protein CEA that is found on some cancer cells. Therefore, the vaccine can tell the immune system to attack cancer cells which make CEA. The investigators are trying to determine whether giving this virus is safe and whether this causes a strong immune system attack on the cancer. ETBX-011 is an investigational drug. - - -
44 Celecoxib, cyclophosphamide K562 (Allogeneic Tumor Cell Vaccine) National Cancer Institute (NCI) I/II To evaluate the safety and effectiveness of tumor cell vaccines in combination with cyclophosphamide and celecoxib in patients with cancers involving the chest. 2010 2011 Source




To go back to the main page, click here

Retrieved from "https://www.dolcera.com/wiki/index.php?title=Lung_Cancer_Trials&oldid=9813"